Healthcare-related businesses centered on pharmaceutical wholesaling and prescription pharmacies
First written in FY2016. 16 of 28 entries say "Restated". Latest entry: FY2026.
1 other company's latest entry also says "Other".
- FY2026Updated the number of group companies and business structureAnnual report
「Our Group (the Company and its affiliated companies) consists of the Company, 43 subsidiaries and 17 affiliates,」
The group structure was updated to 43 subsidiaries and 17 affiliates, reflecting the absorption-type merger of 北陸東邦, the consolidation of ケイ・クリエイト and changes in the composition of affiliates. - FY2026-H1Consolidation Scope UpdatedAnnual report
「Because 株式会社ケイ・クリエイト, formerly an unconsolidated subsidiary, became material, it was included in the scope of consolidation from the interim consolidated accounting period of the current fiscal year, and interim consolidated financial statements were prepared.」
株式会社ケイ・クリエイト was added to the scope of consolidation from the interim consolidated accounting period of the current fiscal year after becoming material. - FY2024Updated the number of group companiesAnnual report
「Our Group (the Company and its affiliated companies) consists of the Company, 57 subsidiaries and 11 affiliates,」
The group is described as consisting of 57 subsidiaries and 11 affiliates, with 4 reportable segments: Pharmaceutical Wholesaling, Dispensing Pharmacies, Pharmaceutical Manufacturing and Sales, and Other Peripheral Businesses. - FY2024-Q1RestatedAnnual report
「There were no material changes in the nature of the businesses operated by the Group, comprising the Company and its affiliates, during the cumulative first quarter of the current consolidated fiscal year.」
Reconfirms that there have been no material changes to the business structure comprising pharmaceutical wholesaling, dispensing pharmacies, Pharmaceutical Manufacturing and Sales, and Other Peripheral Businesses. - FY2023-Q1Consolidation Scope UpdatedAnnual report
「There were no material changes in the nature of the businesses operated by our Group (the Company and its affiliated companies) during the three-month period ended 30 June. Because 株式会社ストレチア, formerly an unconsolidated subsidiary, became material, it was included in the scope of consolidation from the first quarter of the current fiscal year, and quarterly consolidated financial statements were prepared.」
While stating that there were no material changes in the nature of the business, the company added 株式会社ストレチア to the scope of consolidation from the first quarter because it became material. - FY2022Updated the number of group companies and reporting segmentsAnnual report
「Our Group (the Company and its affiliated companies) consists of the Company, 65 subsidiaries and 13 affiliates. Its principal businesses, the role of each business and its relationship with the segments are as follows.」
The group is described as consisting of 65 subsidiaries and 13 affiliates, with 4 reportable segments shown for the full fiscal year: Pharmaceutical Wholesaling, Dispensing Pharmacies, Pharmaceutical Manufacturing and Sales, and Other Peripheral Businesses. - FY2022-Q2RestatedAnnual report
「There were no material changes in the nature of the businesses operated by our Group (the Company and its affiliated companies) during the six-month period ended 30 September. Because 株式会社ネグジット総研, 株式会社e健康ショップ and 株式会社eヘルスケア, formerly unconsolidated subsidiaries, became material, they were included in the scope of consolidation from the first quarter, and quarterly consolidated financial statements were prepared. Accordingly, these 3 companies were added to the former Clinical Trial Site Support and Information Equipment Sales businesses to form Other Peripheral Businesses, resulting in 4 reportable segments: Pharmaceutical Wholesaling, Dispensing Pharmacies, Pharmaceutical Manufacturing and Sales, and Other Peripheral Businesses.」
While reconfirming that there were no material changes in the nature of the business, the disclosure reiterates the inclusion of the 3 companies in the scope of consolidation from the first quarter and the change to 4 reportable segments. - FY2022-Q1Updated the scope of consolidation and reporting segmentsAnnual report
「Because 株式会社ネグジット総研, 株式会社e健康ショップ and 株式会社eヘルスケア, formerly unconsolidated subsidiaries, became material, they were included in the scope of consolidation from the first quarter of the current fiscal year, and quarterly consolidated financial statements were prepared. Accordingly, these 3 companies were added to the former Clinical Trial Site Support and Information Equipment Sales businesses to form Other Peripheral Businesses, resulting in 4 reportable segments: Pharmaceutical Wholesaling, Dispensing Pharmacies, Pharmaceutical Manufacturing and Sales, and Other Peripheral Businesses.」
The 3 companies ネグジット総研, e健康ショップ and eヘルスケア were added to the scope of consolidation, and the former Clinical Trial Site Support and Information Equipment Sales businesses were reorganized into 4 reportable segments, including Other Peripheral Businesses. - FY2021-Q3RestatedAnnual report
「There were no material changes in the nature of the businesses operated by our Group (the Company and its affiliated companies) during the nine-month period ended 31 December. Because 共創未来ファーマ株式会社, formerly an unconsolidated subsidiary, became material, it was included in the scope of consolidation from the first quarter, and quarterly consolidated financial statements were prepared. Accordingly, Pharmaceutical Manufacturing and Sales was added as a new reportable segment.」
While reconfirming that there were no material changes in the nature of the business, the disclosure continues to report the inclusion of 共創未来ファーマ in the scope of consolidation and the addition of the Pharmaceutical Manufacturing and Sales segment. - FY2021-Q2RestatedAnnual report
「There were no material changes in the nature of the businesses operated by our Group (the Company and its affiliated companies) during the six-month period ended 30 September. Because 共創未来ファーマ株式会社, formerly an unconsolidated subsidiary, became material, it was included in the scope of consolidation from the first quarter, and quarterly consolidated financial statements were prepared. Accordingly, Pharmaceutical Manufacturing and Sales was added as a new reportable segment.」
While reconfirming that there were no material changes in the nature of the business, the disclosure reiterates the inclusion of 共創未来ファーマ in the scope of consolidation and the addition of the Pharmaceutical Manufacturing and Sales segment from the first quarter. - FY2021-Q1Updated the scope of consolidation and reporting segmentsAnnual report
「Because 共創未来ファーマ株式会社, formerly an unconsolidated subsidiary, became material, it was included in the scope of consolidation from the first quarter of the current fiscal year, and quarterly consolidated financial statements were prepared. Accordingly, Pharmaceutical Manufacturing and Sales was added as a new reportable segment.」
共創未来ファーマ株式会社 was included in the scope of consolidation after becoming material, and a new Pharmaceutical Manufacturing and Sales segment was added. - FY2020Updated the number of group companiesAnnual report
「Our Group (the Company and its affiliated companies) consists of the Company, 68 subsidiaries and 13 affiliates,」
The number of group companies was updated from 69 subsidiaries and 13 affiliates to 68 subsidiaries and 13 affiliates. - FY2020-Q3RestatedAnnual report
「During the nine-month period ended December 31, there were no material changes in the business activities conducted by the FANUC Group, comprising the Company and its affiliated companies.」
Reconfirms that there have been no material changes to the business structure, which includes pharmaceutical wholesaling, dispensing pharmacies, clinical trial site support and information equipment sales. - FY2020-Q2RestatedAnnual report
「There were no material changes in the nature of the businesses conducted by our Group, comprising the Company and its affiliates, during the six-month period ended September 30.」
Reconfirms that there have been no material changes to the business structure, which includes pharmaceutical wholesaling, dispensing pharmacies, clinical trial site support and information equipment sales. - FY2020-Q1RestatedAnnual report
「There were no material changes in the nature of the businesses operated by the Group, comprising the Company and its affiliates, during the cumulative first quarter of the current consolidated fiscal year.」
Reconfirms that there have been no material changes to the business structure, which includes pharmaceutical wholesaling, dispensing pharmacies, clinical trial site support and information equipment sales. - FY2019Updated the number of group companiesAnnual report
「Our Group (the Company and its affiliated companies) consists of the Company, 69 subsidiaries and 13 affiliates,」
The group is now described as consisting of 69 subsidiaries and 13 affiliates, compared with 76 subsidiaries and 14 affiliates in the previous disclosure. - FY2019-Q3RestatedAnnual report
「During the nine-month period ended December 31, there were no material changes in the business activities conducted by the FANUC Group, comprising the Company and its affiliated companies.」
Reconfirms that there have been no material changes to the business structure, which includes pharmaceutical wholesaling and dispensing pharmacies. - FY2019-Q2RestatedAnnual report
「Our Group is a corporate group operating in the healthcare, health and nursing care fields,」
Reconfirms the business structure as a corporate group operating in the healthcare, health and nursing care fields. - FY2019-Q1RestatedAnnual report
「There were no material changes in the nature of the businesses operated by the Group, comprising the Company and its affiliates, during the cumulative first quarter of the current consolidated fiscal year.」
Reconfirms that there have been no material changes to the business structure, which includes pharmaceutical wholesaling and dispensing pharmacies. - FY2018Updated the number of group companiesAnnual report
「Our Group (the Company and its affiliated companies) consists of the Company, 76 subsidiaries and 14 affiliates,」
The group is now described as consisting of 76 subsidiaries and 14 affiliates, compared with 78 subsidiaries and 16 affiliates in the previous disclosure. - FY2018-Q3RestatedAnnual report
「During the nine-month period ended December 31, there were no material changes in the business activities conducted by the FANUC Group, comprising the Company and its affiliated companies.」
Reconfirms that there have been no material changes to the business structure, which includes pharmaceutical wholesaling and dispensing pharmacies. - FY2018-Q2RestatedAnnual report
「There were no material changes in the nature of the businesses conducted by our Group, comprising the Company and its affiliates, during the six-month period ended September 30.」
Reconfirms that there have been no material changes to the business structure, which includes pharmaceutical wholesaling and dispensing pharmacies. - FY2018-Q1RestatedAnnual report
「Our Group, as a corporate group operating in the healthcare, health and nursing care fields,」
Reconfirms the business structure as a corporate group operating in the healthcare, health and nursing care fields. - FY2017Updated the number of group companiesAnnual report
「Our Group (the Company and its affiliated companies) consists of the Company, 78 subsidiaries and 16 affiliates,」
The group is now described as consisting of 78 subsidiaries and 16 affiliates, compared with 65 subsidiaries and 17 affiliates previously. - FY2017-Q3RestatedAnnual report
「As a corporate group operating in the healthcare, health and nursing care fields,」
Reconfirms the business structure as a corporate group operating in the healthcare, health and nursing care fields. - FY2017-Q2RestatedAnnual report
「As a corporate group operating in the healthcare, health and nursing care fields,」
Reconfirms the business structure as a corporate group operating in the healthcare, health and nursing care fields. - FY2017-Q1RestatedAnnual report
「Our Group is a distribution group operating in the healthcare, health and nursing care fields,」
Reconfirms the business structure as a group operating in the healthcare, health and nursing care fields, centered on pharmaceutical wholesaling and dispensing pharmacies. - FY2016First statedAnnual report
「A distribution group operating in healthcare, health and nursing care, centered on the two businesses of pharmaceutical wholesaling and dispensing pharmacies」
The group consists of 65 consolidated subsidiaries and 17 equity-method affiliates and operates 4 segments: pharmaceutical wholesaling, dispensing pharmacies, clinical trial site support and information equipment sales.